Therapeutic targets in radiotherapy
Therapeutic targets in radiotherapy
复制标题
DOI：
10.1016/s0360-3016(00)01482-6
复制
发表时间：
2001-02-01
影响因子：
7
通讯作者：
Brown, JM
中科院分区：
文献类型：
--
作者：
Brown, JM
背景资料：在过去的5年里，我们对控制哺乳动物细胞对电离辐射反应的基因产物的了解取得了巨大进展，其中许多是提高放射治疗效果的潜在靶点。然而，这种努力的一个主要障碍是需要对肿瘤细胞相对于正常细胞的优先效应。这样的要求只能通过利用肿瘤和正常细胞之间的已知差异来实现，方法：本文综述了肿瘤和正常细胞之间的三个差异，这些差异正在利用分割放射治疗。优先增强肿瘤对放射治疗反应的三种策略是使用法尼基转移酶抑制剂（FTIs）抑制ras活性，抑制表皮生长因子受体（EGFRs），这些策略中的每一种都利用了至少一些肿瘤与其周围正常组织之间的已知差异，并且在临床前研究中与分次辐射结合时，每一种策略都显示出令人鼓舞的结果。对于优先增强癌症敏感性的三种策略中的每一种，临床前和早期临床数据有望成功应用于放射治疗，（C）2001年爱思唯尔科学公司。
Background: Enormous progress has been made in the past 5 years in our understanding of the gene products governing the response of mammalian cells to ionizing radiation, Many of these are potential targets for enhancing the effectiveness of radiotherapy. However, a major barrier to such efforts is the requirement for a preferential effect on tumor vs. normal cells. Such a requirement can only come about by exploiting a known difference between tumor and normal cells,Methods: This review highlights three differences between tumor and normal cells that are being exploited with fractionated radiotherapy.Results: The three strategies to enhance preferentially tumor response to radiotherapy are inhibition of ras activity using farnesyltransferase inhibitors (FTIs), inhibition of epidermal growth factor receptors (EGFRs), and the use of drugs that preferentially kill hypoxic cells, Each of these strategies exploits a known difference between at least some tumors and their surrounding normal tissues, and each has shown encouraging results when combined with fractionated radiation in preclinical studies.Conclusions: For each of the three strategies to enhance preferentially the sensitivity of cancers, the preclinical and early clinical data are promising for their successful application in radiotherapy, (C) 2001 Elsevier Science Inc.